Scil Proteins to collaborate with Martin Luther University Halle-Wittenberg on gastrointestinal tumors

Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, today announced that it has signed a collaboration agreement with the Martin Luther University Halle-Wittenberg to research innovative therapies for gastrointestinal tumors.

The project will be run by Professor Dr. Thomas Seufferlein, head of the University Hospital’s gastroenterology clinic, and will focus on the discovery and characterisation of disease-related molecular structures. Scil Proteins will then use the Company’s proprietary Affilin® platform to identify effective therapeutics and advance them into further clinical development.

Scil Proteins’ Affilin® therapeutics are so called scaffold proteins derived from the human protein Ubiquitin. Affilin® molecules are high affinity binders with excellent target specificity. The Affilin® platform has successfully delivered target specific molecules, which have subsequently shown activity in animal models, within only a few months.

Dr. Ulrike Fiedler, CEO of Scil Proteins, commented: “We are very pleased to have signed this research collaboration with the Martin Luther University Halle-Wittenberg. We look forward to working with Professor Dr. Seufferlein’s team and using our Affilin® technology to discover innovative therapies for gastrointestinal tumors. We hope that the project will allow us to develop new therapeutic options for patients suffering from gastrointestinal cancer.”